Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
72 hedge funds and large institutions have $391M invested in Dicerna Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 16 increasing their positions, 16 reducing their positions, and 5 closing their positions.
440% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 5
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
44% more funds holding
Funds holding: 50 → 72 (+22)
11% more capital invested
Capital invested by funds: $352M → $391M (+$38.2M)
0% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 16
98% less call options, than puts
Call options by funds: $20K | Put options by funds: $1.19M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.91M |
| 2 |
Goldman Sachs
New York
|
+$6.41M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$4.85M |
| 4 |
AG
Artal Group
Luxembourg
|
+$4.58M |
| 5 |
Millennium Management
New York
|
+$3.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$11.1M |
| 2 |
6CM
683 Capital Management
New York
|
-$4.58M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$4.52M |
| 4 |
Renaissance Technologies
New York
|
-$2.92M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.7M |
DRNA Hedge Fund Activity: Q1 2018 in Review
72 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q1 2018, worth a combined $391M — up 11% from $352M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new DRNA positions and 5 closed out — a net gain of 22 holders — while 16 added to existing stakes and 16 trimmed.
The largest buyer was Vanguard Group, adding an estimated $6.91M. The largest seller was RA Capital Management, cutting an estimated $11.1M.
- 72 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q1 2018, up from 50 in Q4 2017.
- Funds reported $391M of Dicerna Pharmaceuticals, Inc. stock for Q1 2018, up 11% quarter-over-quarter.
- 27 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q1 2018 and 5 closed out, a net change of +22 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q1 2018 was Vanguard Group, an estimated $6.91M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q1 2018 was RA Capital Management, an estimated $11.1M sold.
Based on aggregated 13F filings for Q1 2018.